<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04277598</url>
  </required_header>
  <id_info>
    <org_study_id>MARSYAS II</org_study_id>
    <nct_id>NCT04277598</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Safety and Efficacy of APO-2 at Three Different Doses in Patients With Diabetic Foot Ulcer</brief_title>
  <official_title>A Randomized, Placebo-controlled, Double-blind Study to Evaluate Safety and Dose Dependent Clinical Efficacy of APO-2 at Three Different Doses in Patients With Diabetic Foot Ulcer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aposcience AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>FGK Clinical Research GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Aposcience AG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The MARSYAS II study which will be conducted in patients with diabetic foot ulcer (DFU)&#xD;
      consists of a Lead-In Phase for safety assessment of multiple doses of the biologic&#xD;
      investigational medicinal product (IMP) APO-2 and of a Main Phase (Phase II Study) to assess&#xD;
      the efficacy and safety of the IMP. The phase II study will be a randomized study at multiple&#xD;
      clinical centers and it will be double-blind meaning that neither the investigator nor the&#xD;
      treated patient know if the IMP or a placebo is applied; the study will investigate the&#xD;
      safety and clinical efficacy of multiple dose administrations at three dose levels of APO-2&#xD;
      (low dose, medium dose or high dose) compared with placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      APOSEC is a secretome released by cultured, stressed peripheral blood mononuclear cells&#xD;
      (PBMC) in medium. Content analysis revealed that APOSEC harbors a myriad of proteins,&#xD;
      exosomes, lipids, phospholipids, cholesterols as well as antimicrobial peptides. It was shown&#xD;
      that the topical application of APOSEC mixed with a hydrogel, called APO-2, promotes/enhances&#xD;
      wound healing.&#xD;
&#xD;
      The MARSYAS II main study will be a multinational, multicenter, randomized, double-blind,&#xD;
      placebo-controlled, parallel group, dose-ranging phase II study to investigate the safety and&#xD;
      clinical efficacy of multiple dose administrations at three dose levels of APO-2 compared&#xD;
      with placebo in patients with diabetic foot ulcer (DFU).&#xD;
&#xD;
      The main study will be preceded by a safety lead-in period evaluating multiple dose safety&#xD;
      (25 U/ml APO-2) in patients with DFU in a cohort of 12 patients randomized at a ratio of 3:1&#xD;
      between APO-2 and placebo at 2 to 4 study sites. The minimum duration of an individual&#xD;
      patient in the safety lead-in period is 93 days (including screening), with a maximum of&#xD;
      approximately 117 days.&#xD;
&#xD;
      In the main study 120 eligible patients will be randomized at a ratio of 1:1:1:1 between&#xD;
      APO-2 (three doses) and placebo. Patients will be stratified by wound size (at least one&#xD;
      third of patients will need to have wound size &gt; 4 square cm), and randomly assigned to 1 of&#xD;
      4 treatment groups (low dose [12.5 U/ml], medium dose [25 U/ml], high dose [50 U/ml] or&#xD;
      placebo). After randomization, patients will receive IMP three times per week during the&#xD;
      4-week active treatment period. 0.5 ml IMP will be applied per square cm wound surface area&#xD;
      for each dose group.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 9, 2020</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>During Safety Lead In Phase 12 patients will be randomized to one of two study arms at a ratio of 3:1 between APO-2 and placebo.&#xD;
During the Main Phase 120 patients will be randomized to one of the four study arms at a ratio of 1:1:1:1 between APO-2 (three doses) and placebo.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>double blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Wound area reduction after 4 weeks treatment with APO-2</measure>
    <time_frame>week 4 post baseline</time_frame>
    <description>Percentage reduction in wound area from visit 2 (baseline) at day 1 to visit 14 (end of treatment) at week 4</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>&gt;50 % reduction in wound area</measure>
    <time_frame>week 4 post baseline</time_frame>
    <description>Proportion of patients with &gt;50 % reduction in wound area from day 1 (baseline) to week 4 (end of treatment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wound size</measure>
    <time_frame>Day 1 and week 1,2 3,4,6,8,12 post baseline</time_frame>
    <description>Wound size at day 1 and 1, 2, 3, 4, 6, 8 and 12 weeks after day 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with complete wound closure</measure>
    <time_frame>week 4, 6, 8 and 12 post baseline</time_frame>
    <description>Proportion of patients with complete wound closure during 12-week follow-up period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to complete wound closure</measure>
    <time_frame>A priori specification not possible; between baseline and week 12 post baseline</time_frame>
    <description>Time point at which complete wound closure is achieved</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence rate of the ulcer</measure>
    <time_frame>week 4, 6, 8 and 12 post baseline</time_frame>
    <description>Recurrence rate of the ulcer during 12-week follow-up period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical assessment of peripheral neuropathy</measure>
    <time_frame>day 1 and week 4 and 12 post baseline</time_frame>
    <description>Assessment of severity level of peripheral neuropathy using a 10 g monofilament (Semmes-Weinstein) and a standard 128 Hz tuning fork with scaling (0 = no sense, 8 = good sense)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of local IMP tolerability</measure>
    <time_frame>A priori specification not possible; between baseline and week 12 post baseline</time_frame>
    <description>Number of patients with local adverse events or serious adverse events with causal relationship to study medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of wound pain: visual analogue scale</measure>
    <time_frame>day 1 and week 4,6, 8 and 12 post baseline</time_frame>
    <description>Evaluation of wound pain by visual analogue scale (score of 0 cm = no pain, score of 10 cm = worst pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Quality of Life: questionnaire</measure>
    <time_frame>day 1 and week 4 and 12 post baseline</time_frame>
    <description>Evaluation of Quality of Life (QoL) using Wound QoL questionnaire. Answers to each item are coded with numbers (0='not at all' to 5='very much').</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">132</enrollment>
  <condition>Diabetic Foot Ulcer (DFU)</condition>
  <arm_group>
    <arm_group_label>Lead In Phase: APO-2: 25U/ml</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical administration of APO-2, 25 U/ml; 0.5 ml per square cm wound;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lead In Phase: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Topical administration of placebo; 0.5 ml per square cm wound;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Main Phase: APO-2: 12.5 U/ml</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical administration of APO-2, 12.5 U/ml; 0.5 ml per square cm wound;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Main Phase: APO-2: 25 U/ml</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical administration of APO-2, 25 U/ml; 0.5 ml per square cm wound;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Main Phase: APO-2: 50 U/ml</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical administration of APO-2, 50 U/ml; 0.5 ml per square cm wound;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Main Phase: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Topical administration of placebo; 0.5 ml per square cm wound;</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>APO-2</intervention_name>
    <description>APO-2: dose adjusted gel for topical administration.</description>
    <arm_group_label>Lead In Phase: APO-2: 25U/ml</arm_group_label>
    <arm_group_label>Main Phase: APO-2: 12.5 U/ml</arm_group_label>
    <arm_group_label>Main Phase: APO-2: 25 U/ml</arm_group_label>
    <arm_group_label>Main Phase: APO-2: 50 U/ml</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo gel for topical administration.</description>
    <arm_group_label>Lead In Phase: Placebo</arm_group_label>
    <arm_group_label>Main Phase: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient is between 18 and 80 years of age (upper age 70 years of age in Czech&#xD;
             Republic)&#xD;
&#xD;
          2. Patients with Type I or Type II diabetes with a glycosylated hemoglobin (HbA1c) of ≤&#xD;
             12 %, obtained at enrollment or within 30 days prior to study enrollment&#xD;
&#xD;
          3. Patients who have a wound defined as diabetic foot ulcer present for ≥ 4 weeks&#xD;
&#xD;
          4. Foot ulcer Wagner grade I - II or ARMSTRONG grade I-A (superficial, non-infected,&#xD;
             non-ischemic wound not involving tendon, capsules, or bone) or II-A (non-infected,&#xD;
             non-ischemic wound penetrating to tendon or capsule but not to the bone or joint)&#xD;
&#xD;
          5. Estimated foot ulcer surface area between ≥ 1 cm2 and ≤ 8 cm2 as measured at day of&#xD;
             randomization assessed using the eKARE imaging and measurement device&#xD;
&#xD;
          6. A patient with more than one diabetic foot ulcer may be included in the study but only&#xD;
             one ulcer will be selected for the investigational treatment based on Investigator&#xD;
             judgment as far as the ulcer meets the inclusion criteria (the largest ulcer fitting&#xD;
             the inclusion criteria will be selected as index ulcer)&#xD;
&#xD;
          7. Wound area has not changed by more than 30 % between screening visit and randomization&#xD;
             visit (at least 14 days)&#xD;
&#xD;
          8. Adequate arterial blood perfusion measured on the leg with treated wound (ABI [ankle&#xD;
             brachial index] ≥0.9 [the lowest ABI measured value will be used as reference], or toe&#xD;
             pressure &gt; 50 mmHg, or tcPO2 &gt; 40 mmHg) within the past 6 months&#xD;
&#xD;
          9. Patient must adhere to off-loading of the ulcer area (in mobile patients adherence to&#xD;
             off-loading footwear during the study is mandatory)&#xD;
&#xD;
         10. Patient is able to give written informed consent prior to study start and to comply&#xD;
             with the study requirements&#xD;
&#xD;
         11. Women of childbearing potential agree using adequate birth control methods during the&#xD;
             study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of anaphylaxis, known hypersensitivity to sodium alginate, propylene glycol,&#xD;
             methylene-blue or chicken-egg&#xD;
&#xD;
          2. Target ulcer is over a deformity (such as Charcot deformity) that interferes with&#xD;
             off-loading based on investigator's opinion&#xD;
&#xD;
          3. Index wound duration of &gt; 3 years without intermittent healing&#xD;
&#xD;
          4. Clinical evidence of ulcer bed infection or patients requiring intravenous (IV)&#xD;
             antibiotics to treat the index wound infection at time of randomization&#xD;
&#xD;
          5. Current evidence of osteomyelitis, cellulitis, or other evidence of infection&#xD;
             including pus drainage from the wound site, or documented history of osteomyelitis at&#xD;
             the target wound location during the 6 months preceding the screening visit&#xD;
&#xD;
          6. Major uncontrolled medical disorder(s) such as severe uncontrolled leg edema,&#xD;
             concurrent medication, or other issue that renders the patient unsuitable for&#xD;
             participation in the study, including but not limited to: comorbid condition with an&#xD;
             estimated life expectancy of ≤ 12 months, hemoglobin A1c (Hba1c) &gt; 12 % at screening,&#xD;
             patients on dialysis, patients with severe pulmonary (requiring home oxygen,&#xD;
             uncontrolled COPD Gold III/ IV) or cardiovascular conditions (heart failure NYHA IV,&#xD;
             uncontrolled hypertension systolic BP by repeated measurement &gt; 180 mmHg)&#xD;
&#xD;
          7. Raynaud disease or any other severe peripheral microvascular disease, current&#xD;
             diagnosis of vasculitis, or current diagnosis of claudication&#xD;
&#xD;
          8. Dermatologic comorbid disease (e.g. pyoderma gangrenosum, vasculopathy or vasculitic&#xD;
             ulcers), history of Systemic Lupus Erythematosus with elevated anti-DNA antibody&#xD;
             titers, Buerger's disease (thromboangiitis obliterans)&#xD;
&#xD;
          9. Patient currently treated for an active malignant disease or prior diagnosis of an&#xD;
             active malignant disease who is disease free for less than 1 year. Treatment with&#xD;
             anticancer therapy (chemotherapy, immunotherapy, radiotherapy, targeted therapy or&#xD;
             gene therapy) within 3 months before the first administration of investigational&#xD;
             product or at any time during the study.&#xD;
&#xD;
         10. Patient with history of malignancy within the wound; history of radiation therapy to&#xD;
             the wound region&#xD;
&#xD;
         11. Patients who have undergone wound treatments with growth factors, dermal substitutes,&#xD;
             or other biological therapies within the last 30 days or during the study&#xD;
&#xD;
         12. Patients who received oral or parenteral corticosteroids, immunosuppressants, or&#xD;
             cytotoxic agents within 30 days preceding the first study drug administration, or plan&#xD;
             to use these medications during the study period&#xD;
&#xD;
         13. Patients who are pregnant or breastfeeding&#xD;
&#xD;
         14. Mental condition rendering the patient (or the patient's legally acceptable&#xD;
             representative[s]) unable to understand the nature, scope and possible consequences of&#xD;
             the study&#xD;
&#xD;
         15. Patients who are incarcerated, including prisoners or patients compulsorily detained&#xD;
             for treatment of either a psychiatric or physical (e.g., infectious disease) illness&#xD;
&#xD;
         16. Therapy with another investigational agent within thirty days of screening, or during&#xD;
             the study&#xD;
&#xD;
         17. Patients who are considered by the investigator to have a significant disease, which&#xD;
             can impact the study; patients who are considered not suitable for the study by the&#xD;
             investigator&#xD;
&#xD;
         18. Employee at the study site, spouse/partner or relative of any study staff (e.g.&#xD;
             investigator, sub-investigators, or study nurse) or relationship to the sponsor&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hendrik J Ankersmit, Univ.Prof.Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Aposcience AG</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alfred Gugerell, PD Dr.</last_name>
    <phone>+43 (0)1 40 400</phone>
    <phone_ext>69790</phone_ext>
    <email>alfred.gugerell@aposcience.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ghazaleh Gouya-Lechner, PD Dr.</last_name>
    <phone>+43 650 4704206</phone>
    <email>ghazaleh.gouya-lechner@aposcience.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>A.ö. Krankenhaus der Elisabethinen Klagenfurt GmbH; Abteilung für Chirurgie</name>
      <address>
        <city>Klagenfurt am Wörthersee</city>
        <zip>9020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christiane Dreschl, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kepler Universitätsklinikum Linz; Klinik für Dermatologie und Venerologie</name>
      <address>
        <city>Linz</city>
        <zip>4021</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wolfram Hötzenecker, DDr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinic Hietzing; Wiener Gesundheitsverbund</name>
      <address>
        <city>Vienna</city>
        <zip>1130</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Stulnig, Prof.Dr.med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University hospital at St. Anny; Fakultní nemocnice u sv. Anny</name>
      <address>
        <city>Brno</city>
        <zip>65691</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jana Pecová, MUDr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University hospital Vinohrady</name>
      <address>
        <city>Prague 10</city>
        <zip>100 34</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Šilhová, MUDr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Central military hospital - Military university hospital Prague</name>
      <address>
        <city>Prague 6</city>
        <zip>169 02</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johana Venerová, MUDr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Masaryk hospital in Usti nad Labem</name>
      <address>
        <city>Ústí Nad Labem</city>
        <zip>401 13</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Sauer, MUDr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Franziskus - Krankenhaus Berlin, Klinik für Innere Medizin, Angiologie, Diabetologie</name>
      <address>
        <city>Berlin</city>
        <zip>10787</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Berthold Amann, Dr. med.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen, Klinik für Endokrinologie und Stoffwechselerkrankungen</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susanne Reger-Tan, Prof. Dr.Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Podos clinic</name>
      <address>
        <city>Warsaw</city>
        <zip>02-541</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arkadiusz Krakowiecki, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NZOZ &quot;Mikomed&quot;</name>
      <address>
        <city>Łódź</city>
        <zip>94-238</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacek Mikosiński, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 18, 2020</study_first_submitted>
  <study_first_submitted_qc>February 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2020</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

